Camber Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-6,800,000
Closed -$172M 31
2025
Q1
$172M Buy
6,800,000
+1,800,000
+36% +$47.1M 6.12% 5
2024
Q4
$133M Buy
+5,000,000
New +$136M 3.07% 11
2024
Q3
Sell
-2,500,000
Closed -$70M 38
2024
Q2
$70M Hold
2,500,000
1.94% 18
2024
Q1
$69.4M Sell
2,500,000
-1,420,000
-36% -$39.4M 1.7% 18
2023
Q4
$113M Sell
3,920,000
-3,580,000
-48% -$108M 2.88% 11
2023
Q3
$249M Buy
+7,500,000
New +$265M 8.2% 2
2022
Q4
Sell
-2,500,000
Closed -$109M 46
2022
Q3
$109M Buy
+2,500,000
New +$121M 3.35% 10
2021
Q3
Sell
-2,000,000
Closed -$78.3M 42
2021
Q2
$78.3M Buy
+2,000,000
New +$77.8M 2.64% 18

Other funds holding PFE

Camber Capital Management's PFE Position: Q2 2025 in Review

Camber Capital Management reduced its Pfizer (PFE) stake by 40% in Q2 2025, selling an estimated $23.3M and leaving 1,500,000 shares worth $36.4M. The position accounts for 3.41% of the portfolio, ranked #11.

Camber Capital Management first reported a position in PFE in Q4 2024 and has held it in 3 quarters since. The position peaked at $133M in Q4 2024. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

  • Camber Capital Management held 1,500,000 shares of Pfizer worth $36.4M as of Q2 2025.
  • Camber Capital Management sold 1,000,000 Pfizer shares in Q2 2025, an estimated $23.3M.
  • Pfizer made up 3.41% of Camber Capital Management's portfolio in Q2 2025, its #11 holding.
  • Camber Capital Management first reported a position in Pfizer in Q4 2024 and has held it in 3 quarters since.
  • Camber Capital Management's Pfizer position peaked at $133M in Q4 2024.
  • 2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.